180 Life Sciences Corp (ATNF) - Total Assets
Based on the latest financial reports, 180 Life Sciences Corp (ATNF) holds total assets worth $1.01 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of 180 Life Sciences Corp for net asset value and shareholders' equity analysis.
180 Life Sciences Corp - Total Assets Trend (2016–2024)
This chart illustrates how 180 Life Sciences Corp's total assets have evolved over time, based on quarterly financial data.
180 Life Sciences Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
180 Life Sciences Corp's total assets of $1.01 Billion consist of 40.3% current assets and 59.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.9% |
| Accounts Receivable | $41.19K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.62 Million | 59.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how 180 Life Sciences Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of 180 Life Sciences Corp.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 180 Life Sciences Corp's current assets represent 40.3% of total assets in 2024, an increase from 28.0% in 2016.
- Cash Position: Cash and equivalents constituted 35.9% of total assets in 2024, up from 0.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 59.7% of total assets.
180 Life Sciences Corp Competitors by Total Assets
Key competitors of 180 Life Sciences Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
180 Life Sciences Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.07 | 0.19 | 0.07 |
| Quick Ratio | 10.07 | 0.19 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $506.16 Million | $-5.16 Million | $-7.51 Million |
180 Life Sciences Corp - Advanced Valuation Insights
This section examines the relationship between 180 Life Sciences Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 76.81 |
| Latest Market Cap to Assets Ratio | 84.41 |
| Asset Growth Rate (YoY) | 142.7% |
| Total Assets | $12.76 Million |
| Market Capitalization | $1.08 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values 180 Life Sciences Corp's assets at a significant premium (84.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: 180 Life Sciences Corp's assets grew by 142.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for 180 Life Sciences Corp (2016–2024)
The table below shows the annual total assets of 180 Life Sciences Corp from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $12.76 Million | +142.67% |
| 2023-12-31 | $5.26 Million | -73.23% |
| 2022-12-31 | $19.65 Million | -68.67% |
| 2021-12-31 | $62.71 Million | +12.93% |
| 2020-12-31 | $55.53 Million | +7.03% |
| 2019-12-31 | $51.88 Million | +3455.64% |
| 2018-12-31 | $1.46 Million | -98.75% |
| 2017-12-31 | $117.06 Million | +48674.31% |
| 2016-12-31 | $240.00K | -- |
About 180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more